Symbols / PBYI Stock $7.96 -1.00% Puma Biotechnology, Inc.

Healthcare • Biotechnology • United States • NMS
PBYI (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Alan H. Auerbach
Exch · Country NMS · United States
Market Cap 405.16M
Enterprise Value 323.64M
Income 24.38M
Sales 227.18M
FCF (ttm) 44.09M
Book/sh 2.52
Cash/sh 2.00
Employees 179
Insider 10d —
IPO Apr 24, 2012
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 16.58
Forward P/E 22.74
PEG —
P/S 1.78
P/B 3.15
P/C —
EV/EBITDA 8.21
EV/Sales 1.43
Quick Ratio 2.14
Current Ratio 2.38
Debt/Eq 12.42
LT Debt/Eq —
EPS (ttm) 0.48
EPS next Y 0.35
EPS Growth —
Revenue Growth -2.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA 9.48%
ROE 21.62%
ROIC —
Gross Margin 74.46%
Oper. Margin -8.54%
Profit Margin 10.73%
Shs Outstand 50.90M
Shs Float 39.09M
Insider Own 15.49%
Instit Own 77.53%
Short Float 8.77%
Short Ratio 13.77
Short Interest 3.80M
52W High 8.41
vs 52W High -5.35%
52W Low 3.03
vs 52W Low 162.71%
Beta 1.21
Impl. Vol. 38.72%
Rel Volume 1.18
Avg Volume 264.43K
Volume 312.25K
Target (mean) $5.00
Tgt Median $5.00
Tgt Low $5.00
Tgt High $5.00
# Analysts 1
Recom None
Prev Close $8.04
Price $7.96
Change -1.00%
About

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.00
Mean price target
2. Current target
$7.96
Latest analyst target
3. DCF / Fair value
$15.59
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.96
Low
$5.00
High
$5.00
Mean
$5.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-02-28 reit HC Wainwright & Co. Buy → Buy $7
2024-12-23 reit HC Wainwright & Co. Buy → Buy $7
2024-11-20 reit HC Wainwright & Co. Buy → Buy $7
2024-11-08 reit HC Wainwright & Co. Buy → Buy $7
2024-08-02 reit HC Wainwright & Co. Buy → Buy $7
2024-07-26 reit HC Wainwright & Co. Buy → Buy $7
2024-06-04 reit HC Wainwright & Co. Buy → Buy $7
2024-06-03 reit HC Wainwright & Co. Buy → Buy $7
2024-05-20 reit HC Wainwright & Co. Buy → Buy $7
2024-05-03 reit HC Wainwright & Co. Buy → Buy $7
2024-03-01 main HC Wainwright & Co. Buy → Buy $7
2024-02-13 reit HC Wainwright & Co. Buy → Buy $8
2023-09-20 reit HC Wainwright & Co. Buy → Buy $8
2023-08-04 reit HC Wainwright & Co. Buy → Buy $8
2023-06-05 reit HC Wainwright & Co. Buy → Buy $8
2023-05-05 reit HC Wainwright & Co. — → Buy $8
2023-03-06 reit HC Wainwright & Co. — → Buy $8
2022-08-05 main HC Wainwright & Co. — → Buy $8
2022-05-06 main HC Wainwright & Co. — → Buy $12
2021-09-28 up Citigroup Neutral → Buy —
News
RSS: Latest PBYI news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-12 WILSON TROY EDWARD Director — 10,800 $7.20 $77,748
2026-06-12 SENDEROWICZ ADRIAN M Director — 27,000 $7.20 $194,311
2026-06-12 DORVAL ALLISON Director — 11,610 $7.20 $83,579
2026-06-12 STUGLIK BRIAN M Director — 8,100 $7.20 $58,311
2026-06-12 MOYES JAY M Director — 22,000 $7.22 $158,796
2026-06-11 WILSON TROY EDWARD Director — 27,000 $0.00 $0
2026-06-11 SENDEROWICZ ADRIAN M Director — 27,000 $0.00 $0
2026-06-11 DORVAL ALLISON Director — 27,000 $0.00 $0
2026-06-11 STUGLIK BRIAN M Director — 27,000 $0.00 $0
2026-06-11 CESANO ALESSANDRA Director — 27,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
228.37
-0.91%
230.47
-2.19%
235.64
+3.34%
228.03
Operating Revenue
228.37
-0.91%
230.47
-2.19%
235.64
+3.34%
228.03
Cost Of Revenue
58.16
-9.70%
64.40
+2.75%
62.68
+13.77%
55.09
Reconciled Cost Of Revenue
58.16
-9.70%
64.40
+2.75%
62.68
+13.77%
55.09
Gross Profit
170.21
+2.50%
166.06
-3.98%
172.96
+0.01%
172.94
Operating Expense
132.91
-1.62%
135.10
-3.72%
140.31
-1.34%
142.22
Research And Development
62.07
+12.98%
54.94
+9.04%
50.38
-3.56%
52.24
Selling General And Administration
71.21
-11.74%
80.68
-10.29%
89.93
-0.05%
89.98
General And Administrative Expense
71.21
-11.74%
80.68
-8.76%
88.43
-1.72%
89.98
Salaries And Wages
38.95
+4.91%
37.12
-7.99%
40.34
+6.23%
37.98
Other Gand A
32.26
-25.93%
43.56
-9.40%
48.08
-7.53%
52.00
Total Expenses
191.07
-4.23%
199.50
-1.72%
203.00
+2.88%
197.31
Operating Income
37.30
+20.45%
30.97
-5.13%
32.64
+6.25%
30.72
Total Operating Income As Reported
37.30
+20.45%
30.97
-5.13%
32.64
+37.61%
23.72
EBITDA
53.34
+10.95%
48.08
+1.16%
47.52
+117.11%
21.89
Normalized EBITDA
53.34
+10.95%
48.08
+1.16%
47.52
+14.94%
41.34
Reconciled Depreciation
10.94
-5.09%
11.52
+0.04%
11.52
+17.06%
9.84
EBIT
42.40
+16.01%
36.55
+1.52%
36.00
+198.81%
12.05
Total Unusual Items
—
0.00
+100.00%
-0.62
+96.79%
-19.46
Total Unusual Items Excluding Goodwill
—
0.00
+100.00%
-0.62
+96.79%
-19.46
Special Income Charges
—
0.00
+100.00%
-0.62
+96.79%
-19.46
Other Special Charges
—
—
—
19.46
Restructuring And Mergern Acquisition
—
—
0.00
-100.00%
7.00
Write Off
—
0.00
-100.00%
0.62
0.00
Net Income
31.11
+2.75%
30.28
+40.23%
21.59
+1079450.00%
0.00
Pretax Income
35.78
+48.47%
24.10
+6.29%
22.67
+4861.49%
0.46
Net Non Operating Interest Income Expense
-2.54
+67.08%
-7.73
+27.94%
-10.72
+0.50%
-10.78
Interest Expense Non Operating
6.62
-46.82%
12.45
-6.59%
13.33
+14.99%
11.59
Net Interest Income
-2.54
+67.08%
-7.73
+27.94%
-10.72
+0.50%
-10.78
Interest Expense
6.62
-46.82%
12.45
-6.59%
13.33
+14.99%
11.59
Interest Income Non Operating
4.08
-13.67%
4.72
+81.34%
2.60
+220.42%
0.81
Interest Income
4.08
-13.67%
4.72
+81.34%
2.60
+220.42%
0.81
Other Income Expense
1.03
+19.14%
0.86
+13.57%
0.76
+103.90%
-19.48
Other Non Operating Income Expenses
1.03
+19.14%
0.86
+13.57%
0.76
+2810.71%
-0.03
Tax Provision
4.67
+175.61%
-6.18
-670.45%
1.08
+138.02%
0.46
Tax Rate For Calcs
0.00
-37.62%
0.00
+339.66%
0.00
-77.26%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
+100.00%
-4.09
Net Income Including Noncontrolling Interests
31.11
+2.75%
30.28
+40.23%
21.59
+1079450.00%
0.00
Net Income From Continuing Operation Net Minority Interest
31.11
+2.75%
30.28
+40.23%
21.59
+1079450.00%
0.00
Net Income From Continuing And Discontinued Operation
31.11
+2.75%
30.28
+40.23%
21.59
+1079450.00%
0.00
Net Income Continuous Operations
31.11
+2.75%
30.28
+40.23%
21.59
+1079450.00%
0.00
Normalized Income
31.11
+2.75%
30.28
+40.23%
21.59
+40.45%
15.37
Net Income Common Stockholders
31.11
+2.75%
30.28
+40.23%
21.59
+1079450.00%
0.00
Diluted EPS
0.61
-1.61%
0.62
+37.78%
0.45
0.00
Basic EPS
0.62
+0.00%
0.62
+34.78%
0.46
0.00
Basic Average Shares
50.01
+2.80%
48.65
+3.21%
47.13
+5.51%
44.67
Diluted Average Shares
50.65
+3.16%
49.10
+3.26%
47.55
+5.83%
44.93
Diluted NI Availto Com Stockholders
31.11
+2.75%
30.28
+40.23%
21.59
+1079450.00%
0.00
Provision For Doubtful Accounts
-0.36
+30.25%
-0.52
-158.91%
0.88
0.00
Line Item Trend 2023-12-31
Total Assets
230.53
Current Assets
156.19
Cash Cash Equivalents And Short Term Investments
95.94
Cash And Cash Equivalents
84.58
Other Short Term Investments
11.35
Receivables
47.84
Accounts Receivable
47.84
Gross Accounts Receivable
48.72
Allowance For Doubtful Accounts Receivable
-0.88
Other Receivables
0.65
Inventory
7.08
Raw Materials
5.69
Work In Process
0.82
Finished Goods
0.57
Prepaid Assets
3.02
Restricted Cash
—
Other Current Assets
2.31
Total Non Current Assets
74.34
Net PPE
8.65
Gross PPE
16.33
Accumulated Depreciation
-7.68
Properties
0.00
Buildings And Improvements
7.79
Machinery Furniture Equipment
4.76
Other Properties
0.30
Leases
3.78
Goodwill And Other Intangible Assets
60.87
Other Intangible Assets
60.87
Non Current Deferred Assets
0.00
Non Current Deferred Taxes Assets
0.00
Non Current Prepaid Assets
0.21
Other Non Current Assets
4.62
Total Liabilities Net Minority Interest
177.09
Current Liabilities
99.38
Payables And Accrued Expenses
49.33
Payables
6.89
Accounts Payable
6.89
Current Accrued Expenses
42.44
Pensionand Other Post Retirement Benefit Plans Current
10.28
Current Debt And Capital Lease Obligation
38.80
Current Debt
34.00
Other Current Borrowings
34.00
Current Capital Lease Obligation
4.80
Other Current Liabilities
0.97
Total Non Current Liabilities Net Minority Interest
77.70
Long Term Debt And Capital Lease Obligation
72.69
Long Term Debt
65.66
Long Term Capital Lease Obligation
7.03
Other Non Current Liabilities
4.89
Stockholders Equity
53.44
Common Stock Equity
53.44
Capital Stock
0.01
Common Stock
0.01
Share Issued
47.65
Ordinary Shares Number
47.65
Treasury Shares Number
0.00
Additional Paid In Capital
1,398.61
Retained Earnings
-1,345.16
Gains Losses Not Affecting Retained Earnings
-0.00
Other Equity Adjustments
-0.00
Total Equity Gross Minority Interest
53.44
Total Capitalization
119.10
Working Capital
56.80
Invested Capital
153.10
Total Debt
111.49
Net Debt
15.07
Capital Lease Obligations
11.83
Net Tangible Assets
-7.43
Tangible Book Value
-7.43
Non Current Accrued Expenses
0.12
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
41.80
+7.41%
38.92
+44.09%
27.01
+270.65%
-15.83
Cash Flow From Continuing Operating Activities
41.80
+7.41%
38.92
+44.09%
27.01
+270.65%
-15.83
Net Income From Continuing Operations
31.11
+2.75%
30.28
+40.23%
21.59
+1079450.00%
0.00
Depreciation Amortization Depletion
10.94
-5.09%
11.52
+0.04%
11.52
+17.06%
9.84
Depreciation And Amortization
10.94
-5.09%
11.52
+0.04%
11.52
+17.06%
9.84
Other Non Cash Items
—
—
—
7.00
Stock Based Compensation
6.94
-15.78%
8.24
-19.54%
10.25
-13.35%
11.83
Provisionand Write Offof Assets
-0.36
+30.25%
-0.52
-158.91%
0.88
0.00
Asset Impairment Charge
0.00
0.00
-100.00%
0.62
0.00
Deferred Tax
3.25
+145.87%
-7.08
0.00
—
Deferred Income Tax
3.25
+145.87%
-7.08
0.00
—
Operating Gains Losses
0.00
—
—
0.00
Gain Loss On Sale Of PPE
0.00
0.00
0.00
-100.00%
0.00
Change In Working Capital
-10.08
-185.09%
-3.54
+80.20%
-17.85
+59.88%
-44.50
Change In Receivables
-21.28
-230.20%
16.34
+295.33%
-8.37
-6.95%
-7.82
Changes In Account Receivables
-21.28
-230.20%
16.34
+295.33%
-8.37
-6.95%
-7.82
Change In Inventory
3.21
+295.19%
-1.64
+35.63%
-2.55
-198.88%
2.58
Change In Prepaid Assets
-0.33
-132.50%
1.00
+21.95%
0.82
-65.36%
2.37
Change In Payables And Accrued Expense
12.70
+173.83%
-17.20
-141.14%
-7.13
+81.13%
-37.80
Change In Accrued Expense
13.15
+183.13%
-15.82
-108.66%
-7.58
+77.07%
-33.06
Change In Payable
-0.45
+67.17%
-1.38
-407.35%
0.45
+109.48%
-4.73
Change In Account Payable
-0.45
+67.17%
-1.38
-407.35%
0.45
+109.48%
-4.73
Change In Other Working Capital
-1.80
-13.74%
-1.59
-32.80%
-1.20
-29.89%
-0.92
Change In Other Current Assets
-0.17
-120.10%
0.82
-45.88%
1.52
+176.54%
-1.98
Change In Other Current Liabilities
-2.41
-90.37%
-1.27
-34.79%
-0.94
-2.06%
-0.92
Investing Cash Flow
-36.19
-77.06%
-20.44
-6.87%
-19.12
-369.21%
7.10
Cash Flow From Continuing Investing Activities
-36.19
-77.06%
-20.44
-6.87%
-19.12
-369.21%
7.10
Net PPE Purchase And Sale
-0.07
-26.79%
-0.06
+60.00%
-0.14
0.00
Purchase Of PPE
-0.07
-26.79%
-0.06
+60.00%
-0.14
0.00
Capital Expenditure
-0.07
-26.79%
-0.06
+99.56%
-12.64
-80.57%
-7.00
Net Investment Purchase And Sale
-36.12
-77.20%
-20.38
-214.29%
-6.49
-145.98%
14.10
Purchase Of Investment
-108.14
-41.86%
-76.23
-220.12%
-23.81
-392.41%
-4.84
Sale Of Investment
72.02
+28.96%
55.85
+222.30%
17.33
-8.51%
18.94
Net Intangibles Purchase And Sale
0.00
0.00
+100.00%
-12.50
-78.57%
-7.00
Purchase Of Intangibles
0.00
0.00
+100.00%
-12.50
-78.57%
-7.00
Financing Cash Flow
-45.20
-33.54%
-33.85
0.00
-100.00%
12.22
Cash Flow From Continuing Financing Activities
-45.20
-33.54%
-33.85
0.00
-100.00%
12.22
Net Issuance Payments Of Debt
-44.44
-33.33%
-33.33
0.00
0.00
Issuance Of Debt
—
—
0.00
0.00
Repayment Of Debt
-44.44
-33.33%
-33.33
0.00
0.00
Long Term Debt Issuance
—
—
0.00
0.00
Long Term Debt Payments
-44.44
-33.33%
-33.33
0.00
0.00
Net Long Term Debt Issuance
-44.44
-33.33%
-33.33
0.00
0.00
Net Common Stock Issuance
—
0.00
0.00
-100.00%
12.50
Proceeds From Stock Option Exercised
0.13
-13.33%
0.15
0.00
0.00
Net Other Financing Charges
-0.89
-33.33%
-0.67
—
-0.28
Changes In Cash
-39.58
-157.61%
-15.37
-294.90%
7.88
+125.26%
3.50
Beginning Cash Position
71.31
-17.73%
86.68
+10.01%
78.79
+4.65%
75.29
End Cash Position
31.73
-55.51%
71.31
-17.73%
86.68
+10.01%
78.79
Free Cash Flow
41.73
+7.38%
38.86
+170.46%
14.37
+162.95%
-22.83
Interest Paid Supplemental Data
5.82
-45.97%
10.77
-7.39%
11.63
+12.69%
10.32
Income Tax Paid Supplemental Data
1.52
+25.12%
1.22
+65.26%
0.74
+91.93%
0.38
Common Stock Issuance
—
0.00
0.00
-100.00%
12.50
Issuance Of Capital Stock
—
0.00
0.00
-100.00%
12.50
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category